{"source":"kalshi","id":"KXVENGLUSTAT-27","ticker":"KXVENGLUSTAT-27","slug":"KXVENGLUSTAT-27","title":"FDA decision: Venglustat by Sanofi (in 2026)","description":null,"image":null,"icon":null,"active":true,"closed":false,"start_date":"2026-06-17T21:00:00Z","end_date":"2027-01-08T15:00:00Z","closed_time":null,"volume":0.9,"volume_24hr":0.0,"volume_24h_change":null,"normalized_vol_24hr":null,"normalized_volume":0.11688873171806335,"liquidity":null,"open_interest":0.0,"categories":["Finance"],"tags":[],"synthetic":false,"is_group":false,"group_key":null,"parent_event_id":null,"probability":null,"spread":null,"top_outcome":"a full approval or an accelerated approval","top_outcome_probability":0.85,"top_outcome_prob_24h_change":0.0,"top_outcome_volume_24h_change":-0.45,"updated_at":"2026-07-02T23:14:36.226840Z","fetched_at":"2026-07-02T23:14:36.226840Z","added_at":"2026-06-17T21:13:36.802597Z","url":"https://kalshi.com/markets/kxvenglustat/fda-decision-venglustat-by-sanofi-in-2026/kxvenglustat-27","chart_24h":null,"markets":[{"source":"kalshi","id":"KXVENGLUSTAT-27-Y","event_id":"KXVENGLUSTAT-27","slug":"KXVENGLUSTAT-27-Y","question":"What will the FDA's decision be on Venglustat by Sanofi in 2026?","group_item_title":"a full approval or an accelerated approval","description":"If the FDA's decision on Venglustat by Sanofi in 2026 is a full approval or an accelerated approval, the market resolves to Yes.\n\n---\n\nThis market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. \n\nVenglustat is an oral small-molecule drug developed by Sanofi that works by slowing down the body's production of a fatty substance called glucosylceramide, which builds up to harmful levels in people with Gaucher disease — think of it like adjusting a factory's output dial rather than cleaning up the mess after the fact. It belongs to a class called substrate reduction therapy (SRT), meaning it targets the upstream source of the problem rather than replacing a missing enzyme. Because it is a small molecule taken by mouth and designed to cross into the brain, it has potential to address the neurological symptoms that older enzyme-based treatments cannot reach.","image":null,"icon":null,"outcomes":["Yes","No"],"outcome_prices":[0.85,0.15000000000000002],"probability":0.85,"spread":0.06999999999999995,"active":true,"closed":false,"start_date":"2026-06-17T21:00:00Z","end_date":"2027-01-08T15:00:00Z","closed_time":"2027-01-01T04:59:00Z","volume":0.9,"volume_24hr":0.0,"prob_24h_change":0.0,"volume_24h_change":-0.45,"normalized_vol_24hr":null,"normalized_volume":0.12184444069862366,"liquidity":null,"categories":["Finance"],"countries":["United States"],"updated_at":"2026-07-02T23:15:53.059665Z","fetched_at":"2026-07-02T23:14:36.358683Z","added_at":"2026-06-17T21:13:37.045101Z","url":"https://kalshi.com/markets/kxvenglustat/fda-decision-venglustat-by-sanofi-in-2026/kxvenglustat-27","event_title":"FDA decision: Venglustat by Sanofi (in 2026)","chart_24h":[0.85,0.85,0.85,0.85,0.85,0.85,0.85,0.85,0.85,0.85]}],"_meta":{"attribution":"pdata.world — aggregated prediction-market data across 8 platforms","canonical_url":"https://pdata.world/events/kalshi/KXVENGLUSTAT-27","as_of":"2026-07-03T03:44:42.982420Z","docs":"https://api.pdata.world/docs","cite_as":"According to pdata.world (tracking Kalshi): \"FDA decision: Venglustat by Sanofi (in 2026)\" — top market at 85% probability across 1 outcome","source_url":null}}